Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

ABSTRACT:

Objective

ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments.

Research design and methods

Recently diagnosed, drug-naïve patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT.

Results

Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time

SUBMITTER: Kahn SE 

PROVIDER: S-EPMC3292330 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature